FDA approves Medtronic's new pacemaker system:
This article was originally published in Clinica
Executive Summary
The Medtronic Kappa 700 implantable pacing series has received premarket approval from the US FDA. The Minneapolis, Minnesota-based company says its new series of pacemaker systems is able to detect and respond to atrial arrhythmias with appropriate pacing within seconds. Other features of the series include the Remote Assistant, a hand-held monitor which allows patients to check the status of their pacing leads and pacemakers, and Medtronic.Vision software which provides doctors with patient demographics, test results and diagnostic data.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.